Current and future biomarkers for outcomes with immunotherapy in non-small cell lung cancer

Immune checkpoint inhibitors (ICI) have been validated as an effective new treatment strategy in several tumoral types including lung cancer. This remarkable shift in the therapeutic paradigm is in large part due to the duration of responses and long-term survival seen with ICI. However, despite thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Duchemann, Boris, Remon, Jordi, Naigeon, Marie, Cassard, Lydie, Jouniaux, Jean Mehdi, Boselli, Lisa, Grivel, Jonathan, Auclin, Edouard, Desnoyer, Aude, Besse, Benjamin, Chaput, Nathalie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Review Article on Immunotherapy in Other Thoracic Malignancies and Uncommon Populations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264336/
https://www.ncbi.nlm.nih.gov/pubmed/34295689
http://dx.doi.org/10.21037/tlcr-20-839

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264336/
https://www.ncbi.nlm.nih.gov/pubmed/34295689
http://dx.doi.org/10.21037/tlcr-20-839

Ejemplares similares